Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Troy Cox, Dan Handley, Ed Simcox, More

Sophia Genetics: Troy Cox
Sophia Genetics has named former Foundation Medicine CEO Troy Cox chairman of its board of directors, effective March 1. Cox will replace Antoine Duchateau, whom the company said will remain on the board. Cox, who also has held executive positions at US BioOncology and Genentech, joined the Sophia Genetics board in July 2019.
Predictive Oncology: Dan Handley
Predictive Oncology has appointed Dan Handley to its board of directors. Handley is a professor and director of the Clinical and Translational Genome Research Institute of Southern California University. Previously, he was chief scientific officer of the Clinical and Translational Genome Research Institute, a Florida-based non-profit. He also previously served as chief scientific officer for Advanced Healthcare Technology Solutions; as a senior researcher at Procter & Gamble; a senior administrator, researcher, and laboratory manager at the David Geffen UCLA School of Medicine; and as a founding biotechnology inventor for the National Genetics Institute.
LifeOmic: Ed Simcox
Precision medicine software firm LifeOmic has named Ed Simcox as its new chief strategy officer. Simcox joins LifeOmic from the US Department of Health and Human Services, where he served as chief technology officer and acting chief information officer. Prior to this, Simcox was director of US health care strategy, partnerships, and product development for AT&T. He also served as healthcare practice leader at Logicalis US, a global IT firm.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.
The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more